Clinical Implications and Future Research Directions This study represents the first randomized controlled trial evaluating Dapiglutide in adults with obesity
Spotlight on Amylin Combination Strategy 22.5% Weight Loss Achieved in Phase 2 Trial "Amylin Combination Therapy to Address Nausea Side Effects Draws Attention" With Roche making a full-fledged entry into the global obesity drug market, which has been dominated by Eli Lilly and Novo Nordisk, signs are emerging of a major shift in the competitive landscape for obesity treatments
Zhou J, Shang J, Song J, Ping F
Analytical Quality Manufactured to exceed 99% purity and independently tested using HPLC and LC-MS analytical methods to support identity confirmation, purity evaluation, and batch-to-batch consistency
Back to Journals Drug Design, Development and Therapy Volume 19 A Comprehensive Review on the Pharmacokinetics and DrugDrug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Authors Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB , Bae SK Received 17 November 2024 Accepted for publication 14 April 2025 Published 30 April 2025 Volume 2025:19 Pages 35093537 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Prof
